Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Maravai LifeSciences Holdings, Inc. reported revenue of $186M, down 28.3% year over year. Operating margin was -115.9% and net margin -70.4%, on a free-cash-flow margin of -38.1% with capital expenditure at 7.1% of revenue. Every figure is computed directly from MRVI's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $186M | -115.9% | -70.4% |
| FY2024 | $259M | -90.9% | -55.9% |
| FY2023 | $289M | -11.0% | -41.2% |
| FY2022 | $883M | 65.0% | 24.9% |
| FY2021 | $799M | 69.4% | 22.8% |
How does MRVI compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.